Alex Aliper is the Co-Founder and President of EMEA of Insilico Medicine, bioinformatics and deep learning company focused on reinventing drug discovery and biomarker development. He is actively engaged in the efforts of drug discovery and Artificial Intelligence units at Insilico Medicine and manages external collaborations with big pharma and biotech.
He holds a master's degree in bioengineering and bioinformatics and worked in the field of oncology and translational medicine at Bioinformatics Laboratory at the Federal Clinical Research Center for Pediatric Hematology, Oncology and Immunology, one of the largest children's cancer centers in the world. Co-founded Insilico in 2014. He holds a doctorate degree in biology.
Since 2012 he co-authored over 40 peer-reviewed research papers and his research interests lie in the fields of ageing, oncology, drug discovery, drug repurposing, deep learning and translational medicine. His recent research was focused primarily on in silico screening of geroprotectors and applications of generative adversarial networks and reinforcement learning for drug discovery and drug repurposing.

Dr Antebi received his PhD from Massachusetts Institute of Technology, and performed his post-doctoral research at the Johns Hopkins University. He first worked as an Independent Group Leader at the Max Planck Institute for Molecular Genetics, Berlin, and then as an Associate Professor at Baylor College of Medicine, Houston.In 2008, he became a founding Director of the Max Planck Institute for Biology of Ageing, Cologne. His research has focused on unravelling regulatory mechanisms governing animal longevity, and has discovered that hormone driven developmental clocks regulate life span and that small nucleoli are a conserved cellular hallmark of longevity.

Adam Freund has spent 16 years in life science R&D studying the biology of aging. He is founder and CEO of Arda Therapeutics, a biotech company developing therapeutics to remove pathological cells in age-related diseases. Prior to starting Arda, Adam spent 7 years as a Principal Investigator at Calico Life Sciences, a biotech company developing drugs to combat aging. During this time, he initiated and led R&D programs across multiple therapeutic modalities including small and large molecules, gene therapy, and cell therapy. Adam also led a team of computational and experimental biologists to develop a systems biology platform for quantifying aging in preclinical models. Before joining Calico, Adam was a postdoctoral fellow at Stanford University studying telomerase and a graduate student in molecular and cell biology at the University of California, Berkeley, where he studied cellular senescence. He completed his undergraduate at Stanford University in Materials Science and Engineering. He has published over 20 papers and his work has been cited >6,000 times.

Alessandra Zonari holds a Biological Sciences degree (2007) with a Master (2010) and Ph.D. (2013) in Stem Cell and Regenerative Medicine by UFMG (Brazil). Her Ph.D. work was awarded "Best Thesis" by UFMG (Brazil). During her Ph.D., she worked at the Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine- 3Bs Research Group (Portugal), where she continued as a postdoc for a year. She also performed a second postdoc at the University of Coimbra (Portugal). Her expertise is in skin regeneration, skin aging, and tissue engineering. In Portugal, she co-founded Vetherapy, a biotech company that provides stem cell therapies to treat diseases for pets. At the beginning of 2017, Alessandra moved to San Francisco, CA, to join the early team of OneSkin as a Co-Founder and Chief Scientific Officer. At OneSkin, she is dedicated to understanding the mechanism underlying the skin aging process and developing science-based solutions that modulate skin senescent cells. She is a co-inventor of three patents and has published over 20 peer-reviewed papers in scientific journals.

Alexandra is a Co-Founder and Investment Director at Apollo Health Ventures, an early stage investment fund focused on developing interventions that enhance human health and longevity.Alexandra is a trained pharmacist and her PhD studies at Harvard Medical School were focused on investigating the molecular mechanisms that contribute to cellular aging and could be targeted to increase mammalian health span. After her PhD, Alexandra worked with The Boston Consulting Group where she specialized on Pharma and Biotech Strategy to drive the development of innovative therapeutics.
At Apollo, Alexandra is leading the venture creation programs that conceptualize and develop strategies for innovative biotech ventures targeting the aging process at a molecular level. She is also managing the pipeline and diligence process for external investment opportunities, predominantly focusing on preclinical stage biotech companies.

Alex Trapp graduated magna cum laude from the University of Rochester in May 2020, with a BSc in Computational Biology. There, he worked on functional characterizations and single-cell atlases of naked mole-rat hematopoiesis and immunity, with Vera Gorbunova and Andrei Seluanov. Right after graduating, he joined Vadim Gladyshev's lab at Harvard Medical School. Alex works primarily on computational and systems approaches to aging, and more specifically on method development for high-resolution biological age profiling.

Alice Ruixue Ai is a Ph.D. candidate at the University of Oslo (UiO), and the Akershus University Hospital, Norway. In Associate Prof. Evandro F. Fang's lab, she is working on the mechanisms of impaired mitophagy in ageing and age-predisposed Alzheimer's disease (AD). She is applying artificial intelligence on screening and designing of drug candidates against ageing and AD. Before joining the Fang lab, she had a master degree in Oral Medicine from Si-chuan University, China, and published four papers in international peer-reviewed journals in the 3-year master programme. For career development, she aims to become a physician scientist working on healthy oral and brain ageing in the coming years.

Anastasia Georgievskaya is the Co-founder and CEO of Haut.AI, an IT company developing AI-powered computer vision algorithms for skincare and skin health applications. The big goal of Haut.AI is to help people achieve the best skin look by using imaging data, to allow non-specialists in AI to introduce it to daily operations, and in general, help their clients experience healthy aging. Anastasia has 3 years' experience of integrating AI and computer vision algorithms into consumer companies' technology stacks. She has two degrees in bioengineering and biophysics.

Professor Maier, a Fellow of the Royal Australasian College of Physicians (FRACP), graduated in Medicine (MD) 2003 from the University of Lübeck (Germany), was registered 2009 in The Netherlands as Specialist in Internal Medicine-Geriatrics and was appointed Full Professor of Gerontology at Vrije Universiteit Amsterdam (The Netherlands) in 2013. From 2016 to early 2021 Professor Maier has served as Divisional Director of Medicine and Community Care at the Royal Melbourne Hospital, Australia, and as Professor of Medicine and Aged Care at the University of Melbourne, Australia. She continues her career at the National University of Singapore as Co-Director of the Centre for Healthy Longevity. Professor Maier's research focuses on unraveling the mechanisms of ageing and age-related diseases. During the last 10 years she has conducted multiple international observational studies and intervention trials and has published more than 300 peer-reviewed articles, achieving an H index of 54, spearheading the significant contributions of her highly acclaimed innovative, global, multidisciplinary @Age research group. She is a frequent guest on radio and television programs to disseminate aging research and an invited member of several international academic and health policy committees. She currently is the President of The Australian and New Zealand Society for Sarcopenia and Frailty Research.

Anne Brunet is the Michele and Timothy Barakett Endowed Professor and the co-director of the Paul F. Glenn Laboratories for the Biology of Aging at Stanford University. Her lab studies mechanisms of aging and longevity. Brunet received her BS in Biology, summa cum laude, in 1992 from Ecole Normale Supérieure, Paris, France. She immediately began a PhD in the lab of Jacques Pouysségur at the University of Nice, France, which she completed in 1997. Between 1998 and 2003, she did her postdoctoral work at Harvard Medical School in Michael E. Greenberg's laboratory. She has been a professor at Stanford since 2004. She is a member of the Editorial Board for Genes & Development. Brunet's lab works on discovering lifespan-regulating genes and their interactions with the environment. Next, she studies how conserved 'pro-longevity genes' (e.g. FOXO transcription factors) regulate longevity in mammals, the regenerative potential of stem cells, and the nervous system. She uses mammalian tissue culture and C. elegans as model systems to study longevity pathways, dietary restriction, and epigenetic (chromatin-state) regulation of longevity by the environment. In addition, she is developing the extremely short-lived African killifish N. furzeri as a new vertebrate model for aging.

Anne-Ulrike Trendelenburg has been working on various pathways (e.g. TGFb, cellular senescence) involved in age-related diseases (e.g. sarcopenia) and also premature aging diseases (e.g. muscular dystrophies). Dr. Trendelenburg has been acting as a management board member of "MouseAge" (COST action BM1402) and led one of the working groups. She was author of 3 review papers (Cardoso et al 2018, Trendelenburg et al 2019, von Zglinicki et al. 2016).

Alex Zhavoronkov, PhD, is the founder and CEO of Deep Longevity, Inc, a global company developing a broad range of artificial intelligence-based biomarkers of aging and longevity. He is also the founder and CEO of Insilico Medicine (insilico.com), a leader in next-generation artificial intelligence technologies for drug discovery, and biomarker development. Since 2015 he invented critical technologies in the field of generative adversarial networks (GANs) and reinforcement learning (RL) for generation of the novel molecular structures with the desired properties and generation of synthetic biological and patient data. He also pioneered the applications of deep learning technologies for prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signaling pathway modeling. Under his leadership Insilico raised over $50 million in multiple rounds from expert investors, opened R&D centers in 6 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions. Prior to founding Insilico, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, Biogerontology Research Foundation. Since 2012 he published over 130 peer-reviewed research papers, and 2 books including "The Ageless Generation: How Biomedical Advances Will Transform the Global Economy" (Palgrave Macmillan, 2013). He serves on the editorial boards of Aging Research Reviews, Aging, Trends in Molecular Medicine, Frontiers in Genetics, and co-chairs the Annual Aging Research, Drug Discovery and AI Forum (7th annual in 2020) at Basel Life, one of Europe's largest industry events in drug discovery. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.

Prof. Alexey Moskalev is a Corresponding member of Russian Academy of Sciences, Doctor of Biology, the Head of the Laboratory of Geroprotective and Radioprotective Technologies in the Institute of Biology of Komi Scientific Centre of the Ural Branch of the Russian Academy of Sciences, the Head of the Department of Ecology of the Syktyvkar State University named after Pitirim Sorokin, the Head of the Laboratory of Genetics of Aging and Longevity in the Moscow Institute of Physics and Technology

Dr. Aubrey de Grey is a biomedical gerontologist based in Mountain View, California, USA, and is the Chief Science Officer of SENS Research Foundation, a California-based 501(c)(3) biomedical research charity that performs and funds laboratory research dedicated to combating the aging process. In addition, he is Editor-in-Chief of Rejuvenation Research, the world's highest-impact peer-reviewed journal focused on intervention in aging. He received his BA in computer science and Ph.D. in biology from the University of Cambridge. His research interests encompass the characterisation of all the types of self-inflicted cellular and molecular damage that constitute mammalian aging and the design of interventions to repair and/or obviate that damage. Dr. de Grey is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organisations. He is a highly sought-after speaker who gives 40-50 invited talks per year at scientific conferences, universities, companies in areas ranging from pharma to life insurance, and to the public.

Since 2013, Björn Schumacher is full professor and director of the Institute for Genome Stability in Ageing and Diseases (IGSAD) at CECAD Research Centre of the University of Cologne. He received his PhD at the Max Planck Institute for Biochemistry in Munich and conducted his postdoctoral research as EMBO and Marie Curie fellow at the Erasmus Medical Centre in Rotterdam. B.S. received the Eva Luise Köhler Research Award, the Innovation Prize of the State of Northrhine-Westphalia, the European Research Council (ERC) starting grant, and coordinated the FP7 Marie Curie initial training network on chronic DNA damage in ageing (CodeAge). Professor Schumacher is President of the German Society for Ageing Research (DGfA), Vice President of the German Society for DNA Repair (DGDR) and serves on several editorial boards. His research interest focuses on the molecular mechanisms through which DNA damage contributes to cancer development and ageing-associated diseases. Employing the C. elegans system and mammalian disease models, his group uncovered cell-autonomous and systemic responses through which the organism adapts to accumulating DNA damage with ageing. Through the understanding of the basic mechanisms of genome instability-driven ageing, Schumacher aims to contribute to the development of future strategies to prevent ageing-associated diseases.

Brian Chen is an epidemiologist with over 40 peer-reviewed scientific publications on the biology of aging, genomics, epidemiology, chronic diseases and data science, including Dr. Steve Horvath's seminal paper on the "epigenetic clock." He did his postdoctoral research at the National Institute on Aging (NIA) and the National Heart, Lung, and Blood Institute's Framingham Heart Study. He holds a PhD in epidemiology from UCLA and an MPH from the University of California at Berkeley.

Dr. Brian Kennedy is internationally recognized for his research in the basic biology of aging and as a visionary committed to translating research discoveries into new ways of detecting, delaying, preventing and treating human aging and associated diseases. He is a Distinguished Professor in Biochemistry and Physiology at the Yong Loo Lin School of Medicine at National University Singapore and serves as Director of (1) the Centre for Healthy Longevity at the National University Health System, (2) the Healthy Longevity Translational Research Programme, and (3) the Asian Centre for Reproductive Longevity and Equality. Collectively, NUS aging research seeks to demonstrate that longevity interventions can be successfully employed in humans to extend healthspan, the disease-free and highly functional period of life.

From 2010 to 2016, Dr. Kennedy was the President and CEO of the Buck Institute for Research on Aging and he maintained a professorship there through 2020. Dr. Kennedy has an adjunct appointments at the Department of Biochemistry at the University of Washington, where he was a faculty member from 2001 to 2010. In addition, Dr. Kennedy is also actively involved with a number of Biotechnology companies. In addition, Dr. Kennedy serves as a Co-Editor-In-Chief at Aging Cell. Finally, Dr. Kennedy has a track record of interaction in China, where he was a Visiting Professor at the Aging Research Institute at Guangdong Medical College from 2009 to 2014. His Ph.D. was performed in the laboratory of Leonard Guarente at M.I.T., where he published the first paper linking Sirtuins to aging.

Carlos Giovanni Silva-García obtained his Ph.D. in Biomedical Sciences at the National Autonomous University of Mexico where he studied how several adverse conditions affect the physiology of germline, the system required to perpetuate the species. Dr. Silva-García is currently a postdoctoral researcher at T. H. Chan Harvard School of Public Health with Dr. William Mair in the Department of Molecular Metabolism. During his postdoctoral training, he has contributed to understand how epigenetic alterations, a hallmark of aging, affect longevity regulating metabolic changes. Dr. Silva-García's broad scientific interests lie in understanding genetic and non-genetic mechanisms that regulate aging and aging-related disease. In particular, he is interested to study how molecular and cellular mechanisms of external signals that promote longevity regulate metabolic changes and impact age-related diseases, and whether these conditions (positive or negative) can be transmitted to the next generations. Dr. Silva-García's efforts have been recognized by awards from the Harvard Yerby Fellowship and Aramont Fellowship programs. Most recently, he has obtained the K99/R00 Pathway to Independence Award from the National Institute on Aging - NIH.

Dr. Christian Riedel is a trained Biochemist and Molecular Biologist. From 2013 to 2015 he has been a Group Leader at the European Research Institute for the Biology of Ageing in Groningen, Netherlands, and since 2015 he is now a Group Leader at Karolinska Institute in Stockholm, Sweden. His laboratory seeks a better mechanistic understanding of aging and age-related diseases in metazoans, with the aim of eventually interfering with these phenomena and thereby improving human health and quality of life. Specifically, he focuses on three research lines: 1) The mechanistic study of how nutrient-dependent signaling and FOXO transcription factors regulate aging and stress resistance. 2) The development and application of aging-related diagnostics. 3) The development and application of screening strategies to identify geroprotective interventions, i.e. pharmaceuticals.

Dr. Shiqing Cai got his bachelor degree in1997 from China Agricultural University in Beijing，and received his Ph.D. degrees from Shanghai Institute of Plant Physiology & Ecology, Chinese Academy of Sciences in 2002. From 2004 to 2009, he was postdoctoral fellow in Dr. Federico Sesti's lab at University of Medicine & Dentistry of New Jersey. He joined ION in October 2009 as Principal Investigator and the Head of the Laboratory of Ion Channel Regulation. His major research interests are regulation and physiological role of potassium channel.

Cassandra obtained her PhD in Genetics from the Institute of Healthy Ageing at University College London, UK. She joined The Lancet in 2013, first as a Senior Editor at The Lancet Oncology, before being promoted to Deputy Editor at the same journal. During this first stint at The Lancet, Cassandra also held the post of Acting Executive Editor of The Lancet Haematology. In 2018, she left the group to write a popular science book, Enough, which addressed the intersection between preventative medicine, the environment, and nutrition (Hachette, Jan 2021). Cassandra returned to The Lancet in 2020 to became the founding Editor-in-Chief of The Lancet Healthy Longevity. Cassandra has written and spoken widely on a diverse array of health issues; a career highlight was launching an initiative on revolutionising cancer care with US president Joe Biden at the UN headquarters in 2017.

Dr Ewald has a longstanding interest in the molecular biology of healthy aging and age-related pathologies. His curiosity for aging research was ignited by the finding that neurons could regulate aging in model organisms and the finding that meditation could change the expression of stress-associated genes in humans. Fascinated by neurons and the mind, he went to New York to pursue a PhD in Neuroscience with Chris Li working on Alzheimer's Disease (AD) related proteins in C. elegans and determined the molecular mechanisms of how AD proteins affect aging, metabolism, and learning. He did his post-doctoral training with Keith Blackwell at Harvard Medical School discovering how insulin/IGF-1 signaling prolongs extracellular matrix maintenance (Ewald et al., Nature 2015). After a short junior faculty position at the Joslin Diabetes Center and as an Instructor in Medicine at Harvard Medical School he returned to Switzerland to join the Institute for Translational Medicine (ITM) as an assistant professor at ETH Zurich focusing his research on the role of the extracellular matrix during aging (www.ewaldlab.com). Dr Ewald is the founder and currently the president of the Swiss Society for Aging Research (www.ssfar.ch).

Daniela Bakula graduated in Biology from the University of Tübingen, Germany in 2012. She obtained her PhD with the highest honors in 2017 from the University of Tübingen within the International Max-Planck Research School "From Molecules to Organisms". Her PhD work focused on molecular mechanisms regulating autophagy and was awarded with highly competitive dissertation prizes. Daniela Bakula moved to Denmark in 2016, where she did her postdoc in the lab of Morten Scheibye-Knudsen at the Center for Healthy Aging, University of Copenhagen before transitioning into an assistant professorship. Her work focuses on understanding how DNA damage may impact aging. Based on her work she received a DFG fellowship as well as a Lundbeck foundation fellowship and several other grants to fund her research. Further, Daniela Bakula is an associate editor with Frontiers in Aging.

Dario Riccardo Valenzano studied neuroscience at the Scuola Normale Superiore in Italy and did a postdoc at Stanford University in the USA. He currently leads a lab at the Max Planck Institute for Biology of Aging and at the Leibniz Institute on Aging, both in Germany. His research team studies the genomic basis of short/long lifespan across species and investigates the role of commensal gut microbes during aging. His main model system is the naturally short-lived turquoise killifish (Nothobranchius furzeri), which he studies in his lab in Cologne and in its natural habitat in the African savannah.

Dr. Sinclair obtained a BS and a Ph.D. at UNSW, worked as a postdoctoral researcher at M.I.T., was hired at Harvard Medical School in 1999 as an Assistant Professor, and promoted to tenured Professor in 2008. His book Lifespan: Why We Age and Why We Don't Have To, a NYT bestseller, is published in more than 20 languages.
Dr. Sinclair is an inventor on more than 50 patents, 170 papers, an h-index of 103 & cited 73,000+ times. His more than 40 awards include an Excellence in Teaching Award, Harvard, AFAR Fellowship, the Ellison Medical Foundation Scholarships, Genzyme Outstanding Achievement Award, Telluride Technology Award, Innovator of the Year, MERIT Award, Nathan Shock Award, Denham Harman Award, ASMR Medal, Advance Global Australian, Pioneer Award, TIME100's most influential people, TIME magazine's Heathcare 50, Irving Wright Award, AFAR, and is an Officer of the Order of Australia (AO).
He cofounded Sirtris Pharma (Cambridge; NASDAQ:SIRT, bought by GSK), Genocea (Cambridge, MA; NASDAQ:GNCA); Ovascience (NASDAQ:OVAS), Cohbar (Menlo Park NASDAQ:CWBR)), MetroBiotech, ArcBio, Liberty Biosecurity, Galilei, Immetas, EdenRoc Sciences and affiliates, and Life Biosciences and affiliates.
David Sinclair is a founder, equity owner, advisor to, director of, and/or inventor of patents licensed to Metrobiotech, Jumpstart Fertility, Liberty Biosecurity, Animal Biosciences, EdenRoc Sciences, Life Biosciences, Cohbar, Galilei, Spotlight Biosciences, Arc-Bio, Dovetail Genomics, Claret Bio, Selphagy, Iduna, Senolytic Therapeutics, Continuum, Immetas and a licensed unpaid HMS patent to Elysium Health. More info: https://sinclair.hms.harvard.edu/david-sinclairs-affiliations"

David Liaskos is pursuing a PhD in biotechnology and bioengineering at the École Polytechnique Fédérale de Lausanne (EPFL) under the co-supervision of Professor Johan Auwerx and Nagi Bioscience SA, a dynamic Swiss start-up company developing innovative "Organism-on-Chip" technology and bioinformatics tools. He is also involved in an EU Marie Sklodowska-Curie fellowship research project on " Lifespan Regulation Mechanisms in Health and Disease". He studied mechanical engineering at the University of Thessaloniki, Greece, and completed his master thesis at EPFL on cardiovascular biomechanics. His current research focuses on the development of a new class of microfluidic-based bioassays for performing fully automated aging studies using the model organism Caenorhabditis elegans. These microfluidic bioassays can serve as a valid substitute for vertebrate animal testing for a more efficient drug discovery process.

Dudley Lamming is an Associate Professor of Medicine at the University of Wisconsin-Madison, Director of the UW-Madison Comprehensive Diabetes Center Mouse Phenotyping and Surgery Core, and a Research Health Scientist at William S. Middleton VA Hospital. He obtained his B.S. from the Massachusetts Institute of Technology and his Ph.D. at Harvard University, followed by postdoctoral training at the Whitehead Institute for Biomedical Research. Since 2014, his laboratory at UW-Madison has focused on understanding how what, when, and how much we eat regulates health and aging, and the molecular mechanisms which mediate these effects.

Dr. Emmanuelle Passegué, Ph.D. is the Alumni Professor of Genetics & Development and the Director of the Columbia Stem Cell Initiative (CSCI) at Columbia University Irving Medical Center (CUIMC) in New York City. Dr. Passegué received her Ph.D. from the University Paris XI (France), and trained with Dr. Erwin Wagner (Institute for Molecular pathology, Vienna, Austria) and Dr. Irv Weissman (Stanford University, USA) before joining the University of California San Francisco (UCSF) in 2005. Dr. Passegué was a Professor of Medicine in the Hematology/Oncology Division and the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at UCSF until 2016 before joining CUIMC in January 2017. Her research investigates the biology of blood-forming hematopoietic stem cells in normal and deregulated contexts such as hematological malignancies and physiological aging. Dr. Passegué has received a number of awards and prizes including a Scholar Award from the Lymphoma and Leukemia Society, an Outstanding Investigator Award from the NHLBI, and the 2019 William Dameshek Prize from the American Society of Hematology.

Dr. Verdin is the president and chief executive officer of the Buck Institute for Research on Aging. A native of Belgium, Dr. Verdin received his Doctorate of Medicine (MD) from the University of Liege and completed additional clinical and research training at Harvard Medical School. He has held faculty positions at the University of Brussels, the National Institutes of Health (NIH), and the Picower Institute for Medical Research. Dr. Verdin is also a professor of medicine at University of California, San Francisco.

Dr. Verdin studies how metabolism, diet, and small molecules regulate the activity of HDACs and sirtuins, and thereby the aging process and its associated diseases, including Alzheimer's. He has published more than 210 scientific papers and holds more than 15 patents. He is a highly cited scientist (top 1 percent) and has been recognized for his research with a Glenn Award for Research in Biological Mechanisms of Aging and a senior scholarship from the Ellison Medical Foundation. He is an elected member of several scientific organizations, including the American Association for the Advancement of Science, the American Society for Clinical Investigation, and the Association of American Physicians. He also serves on the advisory council of National Institute on Drug Abuse at the National Institutes of Health.

Prof. Evelyne Yehudit Bischof (prev. Ewelina Biskup), MD, MPH, FEFIM, FMH
Affiliated with the Shanghai University of Medicine and Health Sciences
Longevity physician at Human Longevity Inc.
Chief physician associate at University Hospital Renji of Jiaotong University Shanghai, prev. attending physician at the University Hospital Basel. Specialist in internal medicine, with research focus on longevity medicine, Artificial Intelligence (AI) and digital health, precision medicine, biogerontology, and geronto-oncology. Trained a.e. at Harvard Medical School affiliated hospitals (Mass General Hospital,
Beth Israel MD, Dana Farber) and Columbia University NYC, graduated from Dresden Medical School (Germany), Swiss board certified after residency and fellowship at the University Hospitals of Zurich and Basel (Switzerland).
Published over 80 peer-reviewed papers, frequent speaker at scientific and medical conferences in Asia and Europe. Long term member of various medical societies, e.g. European Federation of Internal Medicine, World Academy of Medical Sciences, Swiss Society of Internal Medicine etcc.
Spent a decade practicing medicine, lecturing at medical schools and performing clinical and translational research in New York, Shanghai and Basel, with extensive experience in scientific research and clinical practice at the following well-known and highly reputable institutions: University Hospital of Basel, Fudan Cancer Institute and Hospital; Zhongshan Hospital, Renji Hospital and Shanghai East
Hospital

The Evandro F. Fang group are investigating the molecular mechanisms of human aging, and age-predisposed neurodegeneration, especially Alzheimer's disease (AD). After finished his Ph.D. training in Biochemistry with Chair Professor Tzi Bun Ng at The Chinese University of Hong Kong in 2012, he started a 5-year postdoctoral fellowship at the National Institute on Aging USA with Professor Vilhelm Bohr on DNA repair and mitophagy in accelerated ageing, and with Professor Mark Mattson on strategies to improve neuronal resilience. In September 2017, he established his independent laboratory at The University of Oslo, Norway (https://evandrofanglab.com/). The Fang laboratory is focusing on the molecular mechanisms of how cells clear their damaged and aged mitochondria, a process termed "mitophagy", as well as the roles of the NAD+-mitophagy axis in healthy ageing and AD inhibition. NAD+ is a fundamental molecule in life and health and decreases in ageing (both biological and pathological) and AD. He is fascinated with and actively engaged in moving his laboratory findings to translational applications, as involved in 5+ NAD+-based clinical trials, with the overarching goal to establish novel and safe biological approaches to promote longer and healthier human lives.

He has published over 70 papers in international peer-reviewed journals including papers in Cell, Cell Metabolism, Nature Reviews MCB, and Nature Neuroscience. He has received several awards including The NIH Fellows Award for Research Excellence 2014, 2015, an awardee of the Butler-Williams Scholar on Aging 2016 (USA), a FRIMEDBIO Young Research Talent 2017(Norway), a finalist of the 2017 ERC Starting grant, an awardee of the Norwegian Cancer Society Pink Ribbon 2020 grant, and DKNVS 'scientific award to young scientist in the natural sciences for 2020 (DKNVS' vitenskapelige pris til yngre forskere innen naturvitenskap for 2020) by The Royal Norwegian Society of Sciences and Letters.

He is the founding (co)coordinator of the Norwegian Centre on Healthy Ageing network (NO-Age, www.noage100.com), the Norwegian National anti-Alzheimer's disease Network (NO-AD, www.noad100.com), and the Hong Kong-Nordic Research Network.

Fedor Galkin started working at Insilico Medicine in 2018, and in 2020 transferred to its spin-off Deep Longevity — a Hong Kong startup focused on digital solutions for longevity medicine. He is conducting research on biomarkers of aging and the ways to reverse this process.He is also involved in adapting the aging clock technology for clinical, consumer, and corporate use cases. The deep learning models developed by Deep Longevity are available for academic use at aging.ai and for consumers at young.ai

Dr Cabreiro is a Biochemist, who has worked on understanding the biological mechanisms underlying molecular stress protection, metabolism and ageing. He has pioneered the use of the model organism C. elegans to study drug-microbiota interactions and its effects on metabolism and ageing. In particular, his lab developed a pharmacological pipeline with the potential to unravel drug-diet-microbe-host interactions. His lab combines classical and advanced microbial genetics and high-throughput genomic and chemical approaches, targeted metabolomics and computational approaches to study both host and microbial physiology. Over the years, his lab has identified signaling and biochemical pathways in bacteria regulating metabolite availability with the capacity to regulate host physiology. His new research aims to gain insight into the gut microbial action of drugs in higher organisms including mice and to develop strategies to target the microbiota to treat metabolic disease and aging.

Dr Cabreiro is a Biochemist, who has worked on understanding the biological mechanisms underlying molecular stress protection, metabolism and ageing. He has pioneered the use of the model organism C. elegans to study drug-microbiota interactions and its effects on metabolism and ageing. In particular, his lab developed a pharmacological pipeline with the potential to unravel drug-diet-microbe-host interactions. His lab combines classical and advanced microbial genetics and high-throughput genomic and chemical approaches, targeted metabolomics and computational approaches to study both host and microbial physiology. Over the years, his lab has identified signaling and biochemical pathways in bacteria regulating metabolite availability with the capacity to regulate host physiology. His new research aims to gain insight into the gut microbial action of drugs in higher organisms including mice and to develop strategies to target the microbiota to treat metabolic disease and aging.

Georges Janssens (1985) is Assistant Professor in the Laboratory Genetic Metabolic Diseases, at the Amsterdam UMC in The Netherlands. His work is focused on multi-omics data integration studying the molecular determinants of healthy aging. His research education has taken place in California, the UK, Sweden, and the Netherlands. During his postdoctoral work at the Karolinska institute in Stockholm, he pioneered transcriptome-based machine-learning enabled drug screening, an approach he continues to expand upon today in his independent research line in Amsterdam. Dr. Janssens has been awarded several prestigious fellowships including the FEBS (2017) and the VENI (2019). He has authored over 30 publications, with recent first authorships in journals including Cell Metabolism and Cell Reports, and recent corresponding authorships in journals including EMBO Molecular Medicine, Biogerontology, and Frontiers in Aging. He writes a popular-science blog that distills myths on aging (AgingIsBeautiful.com) and is passionate to develop healthy aging diagnostics and interventions that are accessible to the public.

Gerard Karsenty M.D., Ph.D., is the Paul A. Marks M.D., Professor and Chair of the Department of Genetics and Development at Columbia University Medical center, New York City. In the last 20 years, his laboratory has studied every aspect of skeletal biology ranging from development to physiology. His laboratory deciphered the molecular bases of osteoblast-specific gene expression, a work that culminated in his identification of Runx2 as the master gene of osteoblast differentiation. This was followed by the identification of an entire cascade of transcription factors regulating osteoblast differentiation and of Gcm2 as the master gene of parathyroid gland development. In approaching bone physiology Karsenty proposed that there is a coordinated control endocrine in nature, of bone mass, energy metabolism and fertility. The Karsenty lab has verified in the mouse and whenever possible in humans all tenets of this hypothesis. One of them is that bone should be an endocrine organ regulating energy metabolism and reproduction. This led to the identification of osteocalcin as a bone-derived hormone needed for insulin secretion, glucose homeostasis, testosterone secretion by Leydig cells of the testes and male fertility, brain development cognition and adaptation to exercise. Currently his work focuses through the definition of all functions of osteocalcin in understanding why would bone be an endocrine organ.

Kroemer completed medical school at the University of Innsbruck in Austria and earned a Ph.D. in biology from the Autonomous University of Madrid. Early in his career, Kroemer worked for the Spanish National Research Council. Now based in France, he is a cell biology researcher with INSERM and a Professor of the Faculty of Medicine of Paris Descartes University. Kroemer first discovered the fact that mitochondrial membrane permeabilization is a concrete step in the process of programmed cell death.

In a publication analysis by the news magazine Lab Times, Kroemer was the most highly cited cell biologist for the period between 2007 and 2013. Three other scientists who had worked at Kroemer's lab were also highly ranked in the analysis. In 2007, Kroemer was elected a member of the Academy of Sciences Leopoldina, the national academy of Germany. The same year, he received the organization's Carus Medal. He was named a fellow of the European Academy of Sciences in 2010. In 2012, he won the Leopold Griffuel Prize from the French ARC Foundation for Cancer Research. In 2017, he won the Charles Rodolphe Brupbacher Prize. Kroemer is the editor-in-chief of the journal Cell Death & Disease.

James Peyer also serves as the Chairman of the Board of Sensei Biotherapeutics and holds additional board and executive roles across Cambrian's pipeline. He has spent his entire life dedicated to the mission of finding ways to prevent people from getting diseases like cancer and Alzheimer's instead of waiting for them to get sick. James was previously Founder and Managing Partner at Apollo Ventures, the first global longevity-focused venture capital firm, investing across the US and Europe. Prior to Apollo, James was a biotech R&D specialist at the New York office of McKinsey & Company, serving major pharmaceutical clients. He earned his PhD in stem cell biology at University of Texas Southwestern Medical Center as a National Science Foundation Fellow, and his B.A. with special honors from the University of Chicago.

The major research focus of James L. Kirkland, M.D., Ph.D., is the impact of cellular aging (senescence) on age-related dysfunction and chronic diseases, especially developing methods for removing these cells and alleviating their effects. Senescent cells accumulate with aging and in such diseases as dementias, atherosclerosis, cancers, diabetes and arthritis.
The goal of Dr. Kirkland's current work is to develop methods to remove these cells to delay, prevent, alleviate or partially reverse age-related chronic diseases as a group and extend health span, the period of life free of disability, pain, dependence and chronic disease.

Jan Hoeijmakers research focuses on the mechanism and clinical impact of mammalian DNA repair. His team cloned ~half of the genes involved in nucleotide excision and transcription-coupled repair, enabling elucidation of the underlying molecular mechanisms, and generated the largest set of mouse repair mutants allowing insight into the etiology of human repair syndromes. He discovered that DNA damage and consequent transcription stress are a main cause of ageing and that calorie restriction dramatically delays accelerated aging in mouse repair mutants by reducing DNA damage, resolving at least part of the anti-aging mechanism of reduced nutrition. Clinical application to the first progeroid DNA repair deficient patient even surpassed the benefits in mice, reverting the nutrional guidelines for these syndromes. These findings have wide clinical implications for many aging-related diseases most strongly neurodegeneration, for reducing side effects of chemo- and radiotherapy, and ischemia reperfusion injury associated with surgery and organ transplantation. Jan Hoeijmakers heads research teams in the Princess Máxima Center for Pediatric Oncology (Utrecht), the CECAD in Cologne and the Erasmus Medical Center. For his scientific achievements he has obtained numerous (inter)national awards and distinctions.

Jan Vijg is currently the Director, Center for Single-Cell Omics, School of Public Health, Jiao Tong University School of Medicine, Shanghai. Prior to this he served as an Adjunct Professor, Department of New Biology, Daegu Gyeongbuk Institute of Science and Technology, Daegu, Republic of Korea. His research has long been focused on genomic instability and its relationship with aging, mainly using transgenic mouse and Drosophila models harboring mutational reporter genes. Dr, Vijg is a graduate of the State University of Leiden, The Netherlands with a BA in Biology, MSc in Molecular Biology and a PhD in Molecular Biology.

Jean-Marc Lemaitre started its carreer in 1984 as engeenier at CNRS (National Center for Scientific Research). After a Ph.D. of Molecular and cellular Biology of development at Paris 7 University received in 1995 and a Post-doc at Jacques Monod Institute in Paris, he joined the Institute of Human Genetics of Montpellier (IGH), where he obtained a tenure Senior Scientist position at INSERM (National Institute for Scientific and Medical Research) in 1984. Awarded by the AVENIR INSERM Program in 2006, he first worked as an independent group leader at the Institute of Functional Genomics of Montpellier (IGF), working on Genome plasticity in aging. As major achievements, he demontrated the existence of an overlap between mitosis and S phase in rapid cell of early embryogenesis (Lemaitre et al., JCB 1998), identified CDC6 the only oocyte missing replicating factor translated during maturation to give the competence to replicate to the embryo (Lemaitre et al., Nature 2002), identified mitosis as a key step in the reprogramming of the genome in nuclear transfer experiments (Lemaitre et al., Cell 2005). He demonstrated cellular aging reversibility through a patenetd iPSC reprogramming strategy, as a paradigm shift (Lapasset et al., Genes &Dev 2011). He mapped replication origins in human cells and identified a G-quadruplexes as a consensus sequence for priming (Besnard et al., NSMB 2012) and identified replication timing domain signatures of physiological and accelerated aging (Riveria-Mulla et al., PNAS 2017. He identified DNMT1 as a major actor in the reorganization of chromosomes in SAHFs during senescence induced by oncogene (Sati et al., Mol Cell 2020).
In addition, he is co-founder and advisor of two startup INGRAALYS (dedicated to skin rejuvenation and hair regrowth by reprogramming strategies) and ORGANIPS (dedicated to the production of human organs from iPSC derivatives).

Dr. Jens Brüning is Director of the Max Planck Institute for Metabolism Research in Cologne and Director at the Policlinic for Endocrinology, Diabetes and Preventive Medicine at the University Hospital in Cologne.

His research focusses on elucidating the CNS-dependent regulation of energy and glucose metabolism. These studies revealed a previously unappreciated role for insulin action in the central nervous system (CNS) to control organismal glucose homeostasis and insulin sensitivty. His group has defined distinct Agouti-related peptide (AgRP)-expressing neurons in the hypothalamus as critical mediators of insulin's metabolic actions, revealed the molecular mechanisms of insulin action in these neurons as well as their alterations in obesity.

Joanna Bensz is a precursor in developing pathway of modern prevention in healthcare and longevity. Having spend 20+ years in managing and growing international and Fortune 500 companies across Central and Eastern Europe, Joanna co-founded International Institute of Longevity, bringing together international experts in age science, preventive health and longevity economy contributing to development of the sector in Europe.At the end of 2019 together with Prince Michael of Liechtenstein, she opened first Longevity Center in CEE, a boutique preventive health and longevity company, that focuses on scientifically and medically advanced technologies and protocols for healthy longevity and sustainable health. Center is focusing on preventive health and lifestyle interventions based on in-depth diagnostics, epigenetics and biomarkers of biological age. In October 2021 LC will open its first center in Germany.International education in Strategic and International Marketing complemented with Advanced Leadership Program at IESE, University of Navarra in Barcelona.Member of Business and Innovation sub-group of the Strategic Advisory Board of Longevity International, All Party Parliamentary Group for Longevity in the UK. President of the Longevity Vaduz Roundtable in Liechtenstein. She is considered one of 'Top-50 Women in Longevity ' by Aging Analytics Agency.

Joseph Baur earned his Ph.D. from the University of Texas Southwestern Medical Center in Dallas, Texas, where he studied mechanisms that limit the lifespan of cultured human cells under Drs. Jerry Shay and Woody Wright. He then moved to Harvard Medical School where he trained as a postdoctoral fellow with Dr. David Sinclair. There he developed a strong interest in the regulation of aging and metabolism by sirtuins, a conserved class of enzymes that require nicotinamide adenine dinucleotide (NAD) as a co-substrate. His lab currently studies metabolic and signaling pathways by which nutrient intake can influence longevity, with a particular emphasis on NAD and mTOR.

Jim Mellon is a British entrepreneur and investor with a wide range of interests. Through his private investment company, Burnbrae Group, he has substantial real estate holdings in Germany and the Isle of Man, as well as holdings in private and public companies.
Jim's investment philosophy is underpinned by his ability to recognise emerging trends that give rise to new industries or major shifts in markets. This includes global financial crisis of 2008-2009, as foreseen in the first book Jim co-authored entitled Wake Up!, and subsequently in the new science and technologies detailed in Cracking the Code and Fast Forward.
More recently Jim has established himself as a leader in the nascent field of ageing research and longevity. His groundwork into the field is summarised in the book Juvenescence which he also co-authored.
For decades, scientists have quietly been working away to understand the fundamental mechanisms of ageing. As a result of this progress, scientists have been reproducibly altering the rates of ageing and maximum lifespan in animal models. These discoveries are being translated into humans and will soon give rise to the largest industry on the planet.
Jim and his partners have now set up Juvenescence, a company developing therapies for ageing and the diseases of ageing, to capitalise on this money fountain.
Jim sits on the Board of Trustees of the Buck Institute for Research on Aging, and the American Federation for Aging Research (AFAR). He is also a trustee of Biogerontology Research Foundation and Lifeboat Foundation, is an Honorary Fellow of Oriel College at the University of Oxford and sits on the Advisory Board of the Milken Institute's Centre for the Future of Aging. Jim has been honoured by the AFAR with the George E. and Marie J. Doty Award for his support of ageing research.

Prof de Magalhaes graduated in Microbiology in 1999 from the Escola Superior de Biotecnologia in his hometown of Porto, Portugal, and then obtained his PhD in 2004 from the University of Namur in Belgium. Following a postdoc with genomics pioneer Prof George Church at Harvard Medical School, in 2008 Prof de Magalhaes was recruited to the University of Liverpool. He now leads the Integrative Genomics of Ageing Group which focuses on understanding the genetic, cellular, and molecular mechanisms of ageing. Prof de Magalhaes has authored over 100 publications and given over 100 invited talks, including three TEDx talks.

Judith Campisi received a PhD in biochemistry from the State University of New York Stony Brook, and postdoctoral training in cancer biology at the Dana-Farber Cancer Institute and Harvard Medical School. In 1984, she joined the Boston University Medical School faculty as Assistant and then Associate Professor. She joined the Lawrence Berkeley National Laboratory as Senior Scientist in 1991. In 2002, she started a second laboratory at the Buck Institute for Research on Aging, where she is Professor.
At both institutions, Campisi established a broad program to understand the relationship between aging and disease, with an emphasis on the role of cellular senescence in promoting inflammation, cancer and degenerative diseases. Her laboratory made several pioneering discoveries in these areas, has several long-standing national and international collaborations, and mentors many students and fellows. Her research continues to challenge and alter existing paradigms.
Campisi had received numerous awards, including MERIT awards from the National Institute on Aging, and awards from the AlliedSignal Corporation, Gerontological Society of America and American Federation for Aging Research, the Longevity prize from the IPSEN Foundation, and the first international Olav Thon Foundation prize. She is an elected fellow of the American Association for the Advancement of Science, American Association for Cancer Research, and the National Academy of Sciences. She serves on numerous national and international editorial and scientific advisory boards.

Sinovation Ventures, managing US$2.5 billion dual currency investment funds, is a leading venture capital firm focusing on developing the next generation of Chinese high-tech companies. Prior to founding Sinovation in 2009, Dr. Lee was the President of Google China, and senior executives at Microsoft, SGI, and Apple. Dr. Lee received his Bachelor degree in Computer Science from Columbia University, Ph.D. from Carnegie Mellon University, as well as Honorary Doctorate Degrees from both Carnegie Mellon and the City University of Hong Kong. He is the Co-Chair of Artificial Intelligence Council for World Economic Forum Center for the Fourth Industrial Revolution, Fellow of the Institute of Electrical and Electronics Engineers (IEEE), Times 100 in 2013, WIRED 25 Icons, and followed by over 50 million audience on social media.

In the field of artificial intelligence, Dr. Lee built one of the first game playing programs to defeat a world champion (1988, Othello), as well as the world's first large-vocabulary, speaker-independent continuous speech recognition system. Dr. Lee founded Microsoft Research China, later renamed Microsoft Research Asia, which was named as the hottest research lab by MIT Technology Review. While with Apple, Dr. Lee led AI projects in speech and natural language, which have been featured on Good Morning America on ABC Television and the front page of Wall Street Journal. He has authored 10 U.S. patents, and more than 100 journal and conference papers. Altogether, Dr. Lee has been in artificial intelligence research, development, and investment for more than 30 years. His New York Times and
Wall Street Journal bestselling book AI Superpowers: China, Silicon Valley, and the New World Order (aisuperpowers.com) discusses US-China co-leadership in the age of AI as well as the greater societal impacts brought upon by the AI technology revolution. His new co-authored book AI 2041 will be published in fall 2021 exploring how artificial intelligence will change our world over the next twenty years.

K. Lenhard Rudolph is senior group leader at the Leibniz Institute on Aging – Fritz-Lipmann Institute (FLI) in Jena. From 2012-2017 he was the scientific director of the FLI. He received several prestigious research grants and awards including Emmy-Noether-funding, a Heisenberg-Professorship, the Gottfried-Wilhelm Leibniz award of the DFG, and an advanced grant of the European Research Council (ERC). His main contributions include the first description of the role of telomere dysfunction in stem cell and organism aging. His work showed that alterations in epigenetic stress responses of aging stem cells lead to aberrant activation of developmental pathways and stem cell dysfunction. His current work identifies aging-associated metabolic alterations that limit the function of stem cells to adapt to changes in nutrient availability and the capacity of DR to elongate health and lifespan when applied in late-life.

Kris Verburgh is a medical doctor specialized in aging and longevity and the latest developments in medicine and biotechnology. He is a researcher at the Free University of Brussels and faculty member at Singularity University Benelux where he teaches about the future of medicine and longevity. He is a venture partner at Longevity Vision Fund, a $100 million fund that invests in new technologies to address aging. He wrote his first science book when he was 16 years old and by age 28 he had written four science books. Since a young age he has given talks for many organizations and institutions, including universities, Fortune 100 companies and banks

Kristen earned her Ph.D. in Medical Biophysics from the University of Toronto in 2012, and completed her postdoctoral training at Stanford University, where she was a postdoctoral fellow of the Ellison Medical Foundation / American Federation for Aging Research. She is an expert at developing novel bioinformatics approaches that harness large amounts of data to shed light on mechanisms of aging and age-related disease. Her research has focused on computational drug discovery, biomarkers of aging, and the genetics of exceptional human longevity.

Her research career has been dedicated to investigating the impact of DNA damage on the structure of DNA, cell function and organism health. The DNA in each of our cells is damaged thousands of times per day by exposure to environmental factors, dietary components, chemotherapeutic agents and even endogenous by-products of normal metabolism. Studying patients with rare diseases caused by inherited defects in DNA repair provides important insight into the consequences of DNA damage. These patients have a dramatically increased risk of cancer and age prematurely. We engineered mouse models of these genome instability syndromes as a sensitive tool to test hypotheses about how DNA damage promotes cancer and aging.

Linda Partridge works on the biology of ageing. Her research is directed to understanding the mechanisms by which healthy lifespan can be extended in laboratory model organisms and humans. Her work has focussed in particular on the role of nutrient-sensing pathways and diet, and her primary interest is in geroprotective drugs. She is the recipient of numerous awards, was honoured with a DBE for Services to Science in 2009 and is a Fellow of the Royal Society. She is the founding director of the Max Planck Institute for Biology of Ageing and the Biological Secretary of the Royal Society.

Lisa Melton is Senior News Editor, Nature Biotechnology. Lisa is an immunologist by training, and obtained her PhD in Nutrition and Gut Immunology from Buenos Aires University. She worked in the lab at the National Institutes of Medical Research in Mill Hill then switched to the more gregarious world of science communication. Prior to joining Nature Biotechnology, she wrote for the Economist, the New Scientist, Scientific American and Times. She is guest lecturer in Science Communication at the University of West England. Lisa is based in London.

Maria Birkisdottir is a PhD student in the Department of Molecular Genetics and in the Department of Neuroscience of Erasmus MC, Netherlands, working under the supervision of Prof. dr.J.H.J Hoeijmakers, Dr. Ing. W.P. Vermeij and Dr. D. Jaarsma. Her main research centres on the role of DNA damage accumulation and transcriptional stress as a causal factor of neurodegeneration and the impact of nutritional interventions in preventing neuroaging.

Maria Ermolaeva studied Biochemistry at Lomonosov Moscow State University in Moscow, Russia in 1997-2002 and obtained her PhD from EMBL and Heidelberg University in 2008. Then she joined the newly established CECAD Excellence Cluster of the Cologne University as a postdoc. At CECAD, Maria studied systemic DNA damage responses using C. elegans as a model organism. Dr. Ermolaeva found that germline DNA damage confers systemic stress tolerance by activating the innate immune response and ubiquitin proteasome system. In 2015, she moved to the Leibniz Institute on Aging-Fritz Lipmann Institute in Jena, Germany as a junior group leader. Her group investigates stress tolerance and homeostasis in C. elegans, killifish and human primary cells. The key interest is in interactions of the aging organism with environmental challenges (temperature, diet, light, microbiome) and in preventing aging-induced deterioration of the adaptive stress responses.

Dr. M. Carolina Florian holds a PhD from the University of Milano (Italy). She pursued postdoctoral training at the Institute of Molecular Medicine in Ulm University (Germany) from 2009 to 2015. In 2016, she was awarded an Emmy Noether Grant from the German Research Foundation (DFG) dedicated to outstanding early-career researchers. This grant supported the establishment of her independent research team on Epigenetics of Stem Cell Aging. In 2018, she was appointed as group leader at CMRB (Spain).
Her research in the past 5 years strongly challenged the concept that aging is an irreversible process and showed that it is possible to pharmacologically target the aged-dependent alteration of stem cell epigenetic polarity and functionally rejuvenate aged HSCs in vivo. Somatic stem cells are central for tissue homeostasis and regeneration. Their age-dependent functional decline constitutes a hallmark of tissue attrition upon aging, eventually limiting health-span and lifespan. Dr. Florian's work is committed to further grow the understanding of alterations affecting aged somatic stem cells and she is investigating changes of the epigenetic architecture that drive stem cell aging, to improve tissue attrition with age or even to prevent aging-associated diseases.

Dr. Matt Kaeberlein is a Professor of Laboratory Medicine and Pathology at the University of Washington (UW) School of Medicine, with Adjunct appointments in Genome Sciences and Oral Health Sciences. Dr. Kaeberlein's research interests are focused on biological mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve quality of life. He has published more than 200 scientific papers and has been recognized by several prestigious awards including young investigator awards from the Ellison Medical Foundation and the Alzheimer's Association, the Vincent Cristofalo Rising Start in Aging Research Award, the Murdock Trust Award, the NIA Nathan W. Shock Award, and the Robert W. Kleemeier Award for outstanding research in the field of gerontology from the Gerontological Society of America (GSA). Dr. Kaeberlein has been awarded Fellow status with the American Association for the Advancement of Science (AAAS), the American Aging Association (AGE), and the GSA. Dr. Kaeberlein is currently the CEO and Chair of AGE, Past-President of AGE, has served on the Board of Directors for the Federation of American Societies for Experimental Biology (FASEB) and AGE, and has served as Biological Sciences Chair and on Council for GSA. Dr. Kaeberlein is the founding Director of the University of Washington (UW) Healthy Aging and Longevity Research Institute, the Director of the NIH Nathan Shock Center of Excellence in the Basic Biology of Aging at UW, Director of the Biological Mechanisms of Healthy Aging Training Program, and founder and co-Director of the Dog Aging Project.

Michael is one of the most successful founders of the German-speaking Internet industry.Together with his brother Matthias, he created numerous ventures including lastminute.de and turned it into the largest last-minute travel site in Germany. Most notably, the brothers founded WEB.DE, and after a successful IPO, grew it into one of the country's largest internet portals and online media businesses.After the successful sale of his companies, Michael created the seed-stage venture capital investor Kizoo that came to fund and mentor some of Germany's most promising tech startups including Babbel, Staffbase, and Mambu.Forever Healthy started out more than a decade ago as a personal quest to shed the extremely unhealthy lifestyle he acquired while building WEB.DE, and over time turned into the focus of his entrepreneurial energy: To enable people to vastly extend their healthy lifespan and be part of the first generation to cure aging.Initiatives of Forever Healthy include the evaluation of new rejuvenation therapies, evidenced-based curation of the world's cutting-edge medical knowledge, the annual Undoing Aging Conference, funding research projects on the root causes of aging, and supporting the creation of startups turning that research into therapies for human use.

Professor Kjaer is a highly respected physician, academic and is known for his rigorous scientific vigour. His passion for research has seen him publish in the areas of sports medicine, muscle and tendon adaptation at the structural and mechanical levels as well as at the cellular and molecular level. Particularly, Professor Kjaer is interested in mechanisms of adaptation to muscle and tendon following exercise, disuse, disease and ageing.

Michael MacArthur is a postdoctoral fellow at ETH Zurich researching mechanisms of longevity-extending dietary and pharmacologic interventions. Michael's primary work focuses on mechanisms of dietary amino acid restriction and identifying drugable targets involved in amino acid sensing.

Morten Scheibye-Knudsen is Associate Professor and group leader at the Center for Healthy Aging, University of Copenhagen, Denmark. Besides his research activity, he has been committed to educational programs and his online companies Mitodb.com and Forsøgsperson.dk. The latter has grown to become the largest single provider of study participants in Denmark. Morten Scheibye-Knudsen earned his MD in 2007 and his PhD in 2016 from the University of Copenhagen. After graduation, he worked as physician at Slagelse Hospital and at Nuuk Medical Clinic in Greenland. In 2008, he became a Postdoctoral Fellow at the National Institute on Aging at the NIH in Baltimore, Maryland. His work focused on the cross-talk between DNA repair and mitochondrial function in aging and has been honored by a number of competitive awards. In 2015 he was recruited to start his own research group at the University of Copenhagen, where his research group aims to understand the cellular and organismal consequences of DNA damage in the context of aging. With the ultimate goal to modulate and perhaps treat aging and age-related diseases, allowing everyone to live healthier and longer lives.

Neal Bhadkamkar is a Co-founder and General Partner at Bold Capital Partners. He focuses primarily on companies using exponential technologies to (a) transform healthcare and (b) dramatically increase industrial productivity. Previously he co-founded the early stage venture fund Monitor Ventures, in partnership with the strategy consulting firm Monitor Group, now part of Deloitte. Prior to venture capital, Neal headed engineering at a smart-toy company, which was spun out from Interval Research, a next generation incubator that had been established by Paul Allen. Earlier Neal had headed technology commercialization at Interval, where he also served as a member of the research staff. Neal joined Interval after getting his PhD in Electrical Engineering at Stanford University, where he studied circuits and algorithms that mimicked biological sensory and cognitive processes. Before doing his PhD at Stanford, Neal was a strategy consultant at the Boston Consulting Group, which he joined after receiving his MBA from Harvard Business School. Neal's original degree was in Electrical Engineering from the Indian Institute of Technology, Delhi.

Dr. Nir Barzilai is the founding director of the Institute for Aging Research, the Nathan Shock Center of Excellence in the Basic Biology of Aging and the Paul F. Glenn Center for the Biology of Human Aging Research at Albert Einstein College of Medicine of Yeshiva University (Einstein). He also directs the Longevity Genes Project, a genetics study of over 600 families of centenarians and their children. The participants are all Ashkenazi Jews, a group selected for their genetic homogeneity, which makes it easier to identify significant genetic variations. Dr. Barzilai found that many of the centenarians had very high levels of HDL, or the "good cholesterol." Dr. Barzilai is also co-founder of CohBar, Inc., a biotechnology company developing mitochondria based therapeutics to treat diseases associated with aging.

Dr. Barzilai discovered several "longevity genes" in humans that were validated by others. These include variants in genes involved in cholesterol metabolism (CETP and APOC3), metabolism (ADIPOQ and TSHR) and growth (IGF1R). These genes appear to protect centenarians against major age-related diseases, such as cardiovascular disease, cancer, type 2 diabetes and dementia.

Associate Professor of Medicine
Founding Director of the Step Family Foundation Cardiac Rehabilitation and Wellness Center

Pam Taub, MD is a board-certified cardiologist and founding director of the Step Family Foundation Cardiac Rehabilitation and Wellness Center at UC San Diego. Dr. Taub was responsible for all aspects of creating the center, which provides a comprehensive cardiac rehabilitation program for patients with established heart disease.

Her clinical practice focuses on preventive cardiology, lipidology, as well as women's cardiovascular health. She has extensive clinical trial experience and is active in clinical and translational research. Her research focuses on assessing the impact of behavioral, technological, and pharmacological interventions on cardiometabolic disease. Dr. Taub's is a federally funded researcher with funding from: the National Institutes of Health (Principal Investigator on R01 grant), Department of Defense, Department of Homeland Security and American Heart Association. Dr. Taub is widely published (with over 100 publications, books chapters and abstracts) and has authored high impact publications in top peer-reviewed journals including Cell Metabolism and the Journal of the American College of Cardiology. Dr. Taub holds multiple leadership positions in professional societies, serving as a fellow and board member for the American Society of Preventive Cardiology. She is a fellow and member of the American College of Cardiology Prevention of CV Disease Section Leadership Council. She also serves on American Heart Association Council on Clinical Cardiology (Women in Cardiology Committee). Dr. Taub received her MD from Boston University School of Medicine. She completed her residency in internal medicine at the University of Washington Medical Center in Seattle and her fellowship in cardiovascular medicine at UC San Diego. She is board certified in internal medicine, cardiovascular disease.

Patrick Burgermeister is an expert in life science investing with a double background in molecular biology (Biozentrum Basel) and business administration (HSG Sankt Gallen). He joined Kizoo in 2019 coming from the venture capital group BioMedPartners where he was one of the partners. Moreover, his industry career encompasses also banking (as a senior analyst for pharma/biotech) and pharma (as a senior portfolio manager at Novartis).
Patrick supports various biotech companies as a director on their boards, was a successful business developer for early-stage biotech companies and led collaboration and licensing deals with public and private companies. He headed business development at several companies including Apeiron Biologics and BioVersys.

Group Leader, UMC Utrecht, the Netherlands
Founder and CEO, Cleara Biotech B.V.

For long, I have been interested in the role of cellular damage, which can cause cells to become senescent and drive age-related pathologies. Senescent cells are now established as a cause for at least some aspects of aging and pose exciting candidates for therapeutic removal. One problem that we identified in this approach is that there is no such thing as "just" senescence. Even within seemingly homogeneous populations of senescent cells, there can be a large degree of heterogeneity. It is important to better understand what individual subtypes of senescence are deleterious to health and how these can specifically be targeted.
For this ARDD conference, I will discuss our approaches to unravel senescence heterogeneity as well as our progress in TP53-FOXO4 inhibitory peptides, which we find can selectively eliminate subsets of senescent cells.

Polina Mamoshina is a Chief Scientist at Deep Longevity, Ltd, a Hong Kong-based bioinformatics and deep learning company focused on multiple deep biomarkers of aging dubbed "deep aging clocks" to provide a universal multifactorial measure of human biological age. Her primary research interests include artificial intelligence, deep learning, biomarkers of ageing and disease and drug responses, healthcare data management, healthcare data economy.

Polina graduated from the Department of Genetics of the Moscow State University. She was one of the winners of GeneHack a Russian nationwide 48-hour hackathon on bioinformatics at the Moscow Institute of Physics and Technology attended by hundreds of young bioinformaticians. Polina is involved in multiple deep learning projects at the Pharmaceutical Artificial Intelligence division of Insilico Medicine working on the drug discovery engine and developing biochemistry, transcriptome, and cell-free nucleic acid-based biomarkers of ageing and disease.

Richard Faragher is Professor of Biological Gerontology at the University of Brighton and is past Chair of the British Society for Research on Ageing, the International Association of Biomedical Gerontology and the American Aging Association. He read Biochemistry at Imperial College, London and undertook doctoral studies on human premature ageing at the University of Sussex. His primary research interest is the relationship between cellular senescence and organismal ageing. He is a Fellow of the American Aging Association and holds the Royal Pharmaceutical Society Conference Science Medal for his work on the mechanisms of Werner's syndrome, the Help the Aged 'Living Legend' award for his championship of older people, the Paul F Glenn Award for research into the mechanisms of ageing and the British Society for Research on Ageing's highest honour, the Lord Cohen of Birkenhead Medal.

Professor Faragher has served as a member of the Research Advisory Council of the Charity Research into Ageing and on strategy and funding panels for the BBSRC, the US National Institutes on Ageing and the European Union. From 2005-2008 he was Co-director of the BBSRC-EPSRC SPARC programme, a research network designed to build national capacity to conduct inter-disciplinary ageing research. He is currently a Director of the American Federation for Aging Research, the leading US non-profit organization supporting and advancing healthy aging through biomedical research and serves on the Scientific Advisory Board of the Longevity Vision Fund, an investment fund dedicated to making longevity affordable and accessible to all.

Ryan Smith attended Transylvania University and graduated with a degree in Biochemistry. In that time, he had multiple research internships at the University of Kentucky and the University of Pennsylvania studying large scale protein synthesis and physical chemistry. After graduation, he attended medical school at the University of Kentucky for 2 years. After finishing all the educational curriculum and passing USMLE Step 1 he decided to leave and help open up a pharmacy in the United States that focused on peptide synthesis and formulations for pharmaceutical preparations. Since that time, Tailor Made Compounding has become the 4th fastest growing company in healthcare and 21st fastest growing business in the US. Tailor Made Compounding was the first pharmacy to offer an extensive list of peptides in the US and continues research and expansion for the use of these products for the integrative medicine space. Since then, Ryan has opened many businesses including TruDiagnostic, a company focusing on methylation array-based diagnostics for life extension and preventive healthcare.

Riekelt H. Houtkooper received his PhD degree from the laboratory Genetic Metabolic Diseases of the Academic Medical Center Amsterdam (NL), working under supervision of Prof. Ronald Wanders and Dr. Frédéric Vaz. His research centered on cardiolipin metabolism, particularly in relation to the rare mitochondrial disorder Barth syndrome. Riekelt joined the lab of prof. Johan Auwerx at EPFL Lausanne (Switzerland) for a postdoctoral project geared towards understanding and treating more common metabolic diseases. During these years, he became interested in the metabolic aspects of aging. Early 2012 Riekelt moved back to Amsterdam to start his own group, for which he received funding from NWO and the ERC. Current research in the group focuses on molecular and translational metabolism, both in the context of inborn errors of metabolism and aging.

Rochelle Buffenstein is a senior principal investigator at Calico, an Alphabet, Inc. funded research outfit investigating aging. Previously, she had been a professor of Physiology at the Barshop Institute for Longevity and Aging Studies at the University of Texas Health Science Center at San Antonio. Her research focuses on comparative vertebrate physiology, energetics, cancer biology, and aging. She has worked with marsupials, mole-rats, tenrecs, bats, subterranean mammals, and primates. Her best known work involves exceptional aging—specifically, why naked mole-rats live for so much longer than other rodents. Her lab has investigated theories of aging including oxidative damage theory, the advanced glycation end product theory, and the telomere theory.

Rudi Westendorp (1959) is professor of Medicine at Old age at the Faculty of Health and Medical Sciences at University of Copenhagen, Denmark (2015). He sits at the steering board of the interdisciplinary Center of Healthy Ageing exploring aging from cells to society. Trained at Leiden University, Netherlands he became a consultant in internal medicine and epidemiology and later dedicated himself into geriatrics and gerontology. He was full professor at the Leiden University Medical Center, and chair of the department of old age medicine (2000-2014). He was founding director of the privately funded Leyden Academy on Vitality and Ageing (2007-2014) that conducts research, provides education and pursues societal innovations to improve quality of life of older people. He acquainted ample national and European grants, published more than 600+ original articles with an h-index of 70+, and supervised over 50+ PhD students of which three of them have been appointed full professor. He published the bestseller 'Growing older without feeling old' that is translated in six languages. He was endowed doctor honoris causa by the University of Newcastle, UK (2009), and received a knighthood in the order of the Dutch Lion (2014).

Dr. Mitchell is a senior scientist in the Biology of Healthy Ageing group at ETH Zurich. Her postdoctoral work at the National Institute on Aging in Baltimore MD focused on understanding the sexual dimorphism in response to caloric restriction, testing novel pharmacological interventions to extend lifespan and healthspan, and the validation of a new mouse frailty tool. More recently her work at Harvard University, and now ETH Zurich, has focused on understanding the mechanisms of novel weight loss compounds for obesity and their potential as frailty therapeutics. Dr. Mitchell serves on the editorial board of the Journals of Gerontology Series A Biological Sciences, and is an associate editor for Interventions in Aging, Frontiers in Aging.

Sergey Young is the founder of Longevity Vision Fund, a venture fund that invests in technologies with the potential to disrupt life sciences and healthcare to help people live longer and healthier lives.
Sergey is on the Board of Directors of the American Federation of Aging Research (AFAR) and is the Development Sponsor of upcoming Age Reversal XPRIZE global competition designed to reverse aging.
Sergey is the author of the highly anticipated book 'The Science and Technology of Growing Young ' that will be released in the US and globally on August 24 and is available for pre-order on Amazon. The book is a science-based look into the future of longevity, which is based on interviews with over 30 longevity pioneers.

Sibylle Jäger has been working at L'OREAL Research & Innovation since 2007. Before:
Post-doc at Harvard Medical School, Boston, US: AMPK signaling in skeletal muscle
Post-doc at the Max Planck Institute, Munich, Germany: C. elegans genetics, programmed cell death
PhD at University of Stuttgart, Germany: S. cerevisiae genetics, autophagy, ubiquitin/ proteasome system

The overarching aim for our group is to understand the molecular details of cellular stress responses and how they contribute to human diseases such as cancer and aging-related maladies. We are especially interested in understanding the mechanisms by which the MAP kinases p38 and JNK become activated in response to cellular stress insults such as ribosomal impairment, oxidative stress and high osmolarity, and how such signaling drives or protects against pathological cellular changes. Importantly, the same signaling pathways are crucial for inflammatory responses, adding to the relevance of our work for a range of human diseases.

Suresh Rattan, Ph.D.,D.Sc., is Professor Emeritus of Biogerontology at the Department of Molecular Biology and Genetics, Aarhus University, Denmark. His research areas and expertise include ageing of human cells and application of the concept of mild stress-induced hormesis as a modulator of ageing. He is the discoverer of the healthy-ageing effects of kinetin and zeatin, and other hormetins as the drugs for strengthening and promoting health for survival and longevity. He is the recipient of the Lord Cohen Medal in Gerontology from the British Society for Research on Ageing (BSRA), and an Honorary Doctorate from the Russian Academy of Medical Sciences (St. Petersburg branch). He has published almost 300 scientific articles, and has edited/co-edited 15 books, including books for children, general public and research scientists. He is the founder and Editor-in-Chief of Biogerontology – an international peer reviewed journal published by Springer-Nature. He is the present Chairman of the Biological Section of the European Region of the International Association of Gerontology and Geriatrics (IAGG-ER). His personal website is: www.sureshrattan.com

Dr. Suzanne Angeli was born and raised in New Orleans, Louisiana. She received her B.S. from Tulane University in Cell and Molecular Biology, summa cum laude. After taking a genetics course at Tulane, she became interested in the genetic regulation of disease onset. She decided to further pursue this interest as a PhD student at University of California, San Francisco, where she studied the group of genetically inherited neurodegenerative diseases know as polyglutamine diseases. For her postdoctoral studies, Dr. Angeli realized the importance of integrating the biology of aging to better understand age-related diseases, such as Parkinson's and Alzheimer's disease. She joined the Buck Institute for Research on Aging, where she incorporated the use of the nematode, Caenorhabditis elegans, to further her research on aging and impaired protein homeostasis and their relationship to age-related diseases. Dr. Angeli is currently a Research Scientist at the Buck Institute for Research on Aging.

Professor, Human Genetics and Biostatistics David Geffen School of Medicine, University of California, Los Angeles.
Dr Horvath's research lies at the intersection of aging research, epidemiology, chronic diseases, epigenetics, genetics, and systems biology (notably WGCNA). He works on all aspects of biomarker development with a particular focus on genomic biomarkers of aging. He developed a highly accurate DNA methylation based biomarker of aging known as the pan tissue epigenetic clock. Salient features of this epigenetic clock include its high accuracy and its applicability to a broad spectrum of tissues and cell types. Horvath co-authored the first articles demonstrating that epigenetic age predicts life-expectancy and is positively associated with obesity, HIV infection, Alzheimer's disease, Down syndrome, cognitive decline, Parkinson's disease, Huntington's disease, early menopause, Werner syndrome. Recent work describes powerful epigenetic predictors of healthspan.

Thomas A. Rando is an American neurologist. Rando is best known for his research on basic mechanisms of stem cell biology and the biology of aging, as well as for contributions to the study of the muscular dystrophies and the emerging field of regenerative rehabilitation. He is a Professor of Neurology and Neurological Sciences at Stanford University School of Medicine, where he is founding director of the Glenn Center for the Biology of Aging. Rando is also Chief of Neurology at the VA Palo Alto Health Care System.

The Wyss-Coray research team studies brain aging and neurodegeneration with a focus on age-related cognitive decline and Alzheimer's disease. The lab is following up on earlier discoveries which showed circulatory blood factors can modulate brain structure and function and factors from young organisms can rejuvenate old brains. Current studies focus on the molecular basis of this systemic communication with the brain by employing a combination of genetic, cell biology, and proteomics approaches in model organisms and humans.
The lab is part of the Glenn Center for Aging at Stanford University, the Stanford Neurosciences Institute's Brain Rejuvenation Project, The NIH Alzheimer's Disease Research Center, and it is funded by the American Heart Association / Allen Initiative, the National Institute on Aging, and the NOMIS Foundation.

Vadim Gladyshev is a Professor of Medicine at Brigham and Women's Hospital, Harvard Medical School, Director of the Center for Redox Medicine, and Associate Member of the Broad Institute. He obtained all his degrees from Moscow State University, followed by postdoc training at the National Institutes of Health and a first faculty position at the University of Nebraska. He seeks to understand the nature of aging and to define the principles of lifespan control. His lab applies high-throughput and computational approaches to achieve systems level understanding of the aging process and develop interventions that extend lifespan

Dr. Valter Longo is the Edna M. Jones Professor of Gerontology and Biological Sciences and Director of the Longevity Institute at the University of Southern California –Leonard Davis School of Gerontology, Los Angeles, one of the leading centers for research on aging and age-related disease. Dr. Longo is also the Director of the Longevity and Cancer Program at the IFOM Institute of Molecular Oncology in Milan, Italy.

Dr. Longo studied biochemistry as an undergraduate at the University of North Texas, and received his PhD in Biochemistry from UCLA, where he worked under calorie restriction guru Roy Walford, MD. He completed his postdoctoral training in neurobiology with longevity pioneer, Caleb Finch, PhD. He also received extensive training in immunology, endocrinology, microbiology, genetics, molecular biology, and pathology.

His studies focus on the fundamental mechanisms of aging in simple organisms and mice and on how these mechanisms can be translated to humans. The Longo laboratory has identified some of the key genetic pathways that regulate aging in simple organisms and has demonstrated that the inactivation of such pathways can reduce the incidence or progression of multiple diseases in mice and humans. His laboratory has also developed both dietary and genetic interventions that protect normal cells while sensitizing cancer cells to chemotherapy— interventions now being tested in many US and European hospitals.

Vera Gorbunova is an endowed Professor of Biology at the University of Rochester and a co-director of the Rochester Aging Research Center. Her research is focused on understanding the mechanisms of longevity and genome stability and on the studies of exceptionally long-lived mammals. Dr. Gorbunova earned her B.Sc. degrees at Saint Petersburg State University, Russia and her Ph.D. at the Weizmann Institute of Science, Israel. Dr. Gorbunova pioneered comparative biology approach to study aging. She also investigates the role of genomic instability and transposable elements in aging and disease. Recently she demonstrated that LINE1 elements trigger innate immune response that drives age-related sterile inflammation. She has more than 100 publications including publications in high profile journals such as Nature, Science and Cell. Her work received awards of from the Ellison Medical Foundation, the Glenn Foundation, American Federation for Aging Research, and from the National Institutes of Health. Her work was awarded the Cozzarelli Prize from PNAS, prize for research on aging from ADPS/Alianz, France, Prince Hitachi Prize in Comparative Oncology, Japan, and Davey prize from Wilmot Cancer Center.

Dr. He has been serving as Executive Chairman of Human Longevity Inc since July 2019. Prior to HLI, Dr. He was the CEO of OriGene Technologies, Inc. He also is the founder and General Partner of Emerging Technology Partners, LLC (ETP), a life sciences focused venture fund established since 2000. Dr. He has been involved in founding or funding over 80 biotech companies throughout his career. Dr. He is current Chairman fo Genetron Health (NASDAQ: GTH) and Chairman and CEO of Casi Pharmaceuticals, Inc. (NASDAQ: CASI). Dr. He was one of the first few scientists at Human Genome Sciences which was acquired by GSK. Prior to HGS, He was a research fellow at Massachusetts General Hospital and Mayo Clinic. Dr. He is an author to more than 30 research publications and inventor of over 30 issued patents. Dr. He received his Ph.D. in Molecular Biology from Baylor College of Medicine and received an M.B.A. degree from the Wharton School.

Yousin Suh, Ph.D., is the Charles and Marie Robertson of Reproductive Sciences in Obstetrics and Gynecology, Professor of Genetics and Development, and Director of Reproductive Aging in Obstetrics and Gynecology in the Vagelos College of Physicians and Surgeons at Columbia University. She investigates the (epi)genetic component that underlies the interface of intrinsic aging and disease. The approach she follows is based on the identification of (epi)genome sequence variants associated with age-related disease risk or its opposite, i.e., an unusual resistance to such disease. For this purpose her target populations are either cohorts of middle-aged individuals followed longitudinally for signs of all major age-related diseases, or cohorts of extremely long-lived individuals who managed to ward off such diseases. To tackle the key problem of identifying the functional impact of any observed association, she applies specific functional tests, including in silico modeling, cell culture assays and mouse models. Discoveries thus far made include novel, rare alleles associated with extreme longevity, sirtuin variants that confer risk for heart disease, functional non-coding variants in the gene desert Chr. 9p21 locus underlying multiple age-related diseases, longevity-associated miRNAs, and epigenetic signatures of cellular senescence. Her contributions in the field have been recognized by the Glenn Award for Research in Biological Mechanisms of Aging. She has organized numerous international symposiums on functional genomics of aging, is on the Editorial Boards of numerous Journals including PLoS Genetics and Aging Cell as an Associate Editor, and participates in advisory committee members for several research institutions and companies.

EMBO postdoctoral researcher at the Max Planck Institute for Biology of Ageing, Cologne, Germany. His research focuses on repurposing existing drugs for interventions of ageing and age related diseases. First cohort of European Crucible for future research leader.